Known and suggested biomarkers for T2DM.

Novel biomarkers are key to addressing the ongoing pandemic of type 2 diabetes mellitus. While new technologies have improved the potential of identifying such biomarkers, at the same time there is an increasing need for informed prioritization to ensure efficient downstream verification. We have built BALDR, an automated pipeline for biomarker comparison and prioritization in the context of diabetes. BALDR includes protein, gene, and disease data from major public repositories, text-mining data, and human and mouse experimental data from the IMI2 RHAPSODY consortium. These data are provided as easy-to-read figures and tables enabling direct comparison of up to 20 biomarker candidates for diabetes through the public website https://baldr.cpr.ku.dk.

新型生物标志物（biomarker）是应对当前仍在持续的2型糖尿病（type 2 diabetes mellitus）大流行的关键所在。尽管新兴技术提升了此类生物标志物的识别潜力，但与此同时，也愈发需要基于充分依据的优先级排序，以保障下游验证工作的高效推进。我们开发了BALDR，一款面向糖尿病场景的生物标志物比较与优先级排序自动化流程。BALDR整合了来自主流公共存储库的蛋白质、基因与疾病数据、文本挖掘数据，以及IMI2 RHAPSODY联盟提供的人类与小鼠实验数据。用户可通过公开网站https://baldr.cpr.ku.dk，以直观易懂的图表与表格形式获取上述数据，实现对最多20种糖尿病候选生物标志物的直接对比分析。